OSE Immunotherapeutics Says its IBD Candidate OSE-127 Could Help Treatment-resistant Patients
News
OSE Immunotherapeutics presented promising data from preclinical experiments of its investigational treatment OSE-127 (Effi-7) for inflammatory bowel disease (IBD) at FOCIS 2017, the Federation of Clinical Immunology Societies, held June 14-17 in ... Read more